StockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

Research analysts at StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

NASDAQ:BLPH opened at $0.04 on Tuesday. The firm’s fifty day simple moving average is $0.04 and its 200-day simple moving average is $0.05. The stock has a market cap of $440,388.00, a PE ratio of -0.04 and a beta of 0.70. Bellerophon Therapeutics has a fifty-two week low of $0.03 and a fifty-two week high of $0.10.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.